Ignite Creation Date:
2025-12-24 @ 11:35 PM
Ignite Modification Date:
2026-01-02 @ 1:54 PM
Study NCT ID:
NCT05603156
Status:
UNKNOWN
Last Update Posted:
2022-11-02
First Post:
2022-10-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
IIT2022033
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None